Increased Serum Free Light Chains Precede the Presentation of Immunoglobulin Light Chain Amyloidosis

被引:62
|
作者
Weiss, Brendan M. [1 ]
Hebreo, Joseph [2 ]
Cordaro, Daniel V. [3 ]
Roschewski, Mark J. [3 ]
Baker, Thomas P. [3 ]
Abbott, Kevin C. [3 ]
Olson, Stephen W. [3 ]
机构
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] Naval Med Ctr San Diego, San Diego, CA USA
[3] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA
关键词
UNDETERMINED SIGNIFICANCE MGUS; PRIMARY SYSTEMIC AMYLOIDOSIS; MONOCLONAL GAMMOPATHY; MULTIPLE-MYELOMA; GERMLINE GENE; DIAGNOSIS; ABNORMALITIES; INVOLVEMENT; PROGRESSION; ANTIBODIES;
D O I
10.1200/JCO.2013.50.0892
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Patients with immunoglobulin light chain amyloidosis (AL amyloidosis) generally present with advanced organ dysfunction and have a high risk of early death. We sought to characterize monoclonal immunoglobulin (M-Ig) light chains before clinical presentation of AL amyloidosis. Patients and Methods We obtained prediagnostic sera from 20 cases with AL amyloidosis and 20 healthy controls matched for age, sex, race, and age of serum sample from the Department of Defense Serum Repository. Serum protein electrophoresis with immunofixation and serum free light chain (FLC) analysis were performed on all samples. Results An M-Ig was detected in 100% of cases and 0% of controls (P < .001). The M-Ig was present in 100%, 80%, and 42% of cases at less than 4 years, 4 to 11 years, and more than 11 years before diagnosis, respectively. The median FLC differential (FLC-diff) was higher in cases compared with controls at all time periods, less than 4 years (174.8 v 0.3 mg/ L; P < .001), 4 to 11 years (65.1 v 2.2 mg/ L; P < .001), and more than 11 years (4.5 v 0.4 mg/ L; P = .03) before diagnosis. The FLC-diff was greater than 23 mg/ L in 85% of cases and 0% of controls (P < .001). The FLC-diff level increased more than 10% per year in 84% of cases compared with 16% of controls (P < .001). Conclusion Increase of FLCs, including within the accepted normal range, precedes the development of AL amyloidosis for many years. (C) 2014 by American Society of Clinical Oncology
引用
收藏
页码:2699 / +
页数:7
相关论文
共 50 条
  • [21] Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies
    Kumar, Shaji
    Larson, Dirk R.
    Dispenzieri, Angela
    Therneau, Terry M.
    Murray, David L.
    Bergsagel, P. Leif
    Kyle, Robert A.
    Rajkumar, S. Vincent
    BLOOD CANCER JOURNAL, 2019, 9 (6)
  • [22] The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Waldenstrom Macroglobulinemia
    Leleu, Xavier
    Xie, Wanling
    Bagshaw, Meghan
    Banwait, Ranjit
    Leduc, Renee
    Roper, Nitin
    Weller, Edie
    Ghobrial, Irene M.
    CLINICAL CANCER RESEARCH, 2011, 17 (09) : 3013 - 3018
  • [23] Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine
    Palladini, Giovanni
    Russo, Paola
    Bosoni, Tiziana
    Verga, Laura
    Sarais, Gabriele
    Lavatelli, Francesca
    Nuvolone, Mario
    Obici, Laura
    Casarini, Simona
    Donadei, Simona
    Albertini, Riccardo
    Righetti, Gabriella
    Marini, Maddalena
    Graziani, Maria Stella
    D'Eril, Gian Vico Melzi
    Moratti, Remigio
    Merlini, Giampaolo
    CLINICAL CHEMISTRY, 2009, 55 (03) : 499 - 504
  • [24] The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis
    Dinner, Shira
    Witteles, Wesley
    Witteles, Ronald
    Lam, Anthony
    Arai, Sally
    Lafayette, Richard
    George, Tracy I.
    Schrier, Stanley L.
    Liedtke, Michaela
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (03) : 367 - 372
  • [25] Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018
    Gertz, Morie A.
    BLOOD CANCER JOURNAL, 2018, 8
  • [26] The use of serum free light chain dimerization patterns assist in the diagnosis of AL amyloidosis
    Gatt, Moshe E.
    Kaplan, Batia
    Yogev, Dean
    Slyusarevsky, Elana
    Pogrebijski, Galina
    Golderman, Sizilia
    Kukuy, Olga
    Livneh, Avi
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (01) : 86 - 92
  • [27] Serum free light chain analysis
    Davids, Matthew S.
    Murali, Mandakolathur R.
    Kuter, David J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (10) : 787 - 790
  • [28] Treatment Tolerability in Patients with Immunoglobulin Light Chain Amyloidosis
    Rizio, Avery A.
    White, Michelle K.
    McCausland, Kristen L.
    Quock, Tiffany P.
    Guthrie, Spencer D.
    Yokota, Miyo
    Bayliss, Martha S.
    AMERICAN HEALTH AND DRUG BENEFITS, 2018, 11 (08) : 430 - 437
  • [29] Stem cell transplantation for immunoglobulin light chain amyloidosis
    Sher, Taimur
    Gertz, Morie A.
    CURRENT PROBLEMS IN CANCER, 2017, 41 (02) : 129 - 137
  • [30] Analytical performance of the serum free light chain assay
    Briand, Pierre-Yves
    Decaux, Olivier
    Caillon, Helene
    Grosbois, Bernard
    Le Treut, Andre
    Guenet, Lucienne
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2010, 48 (01) : 73 - 79